On September 10, 2021 Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, reported that CEO, Dr James Garner, will be presenting at the HC Wainwright 23rd Annual Global Investment Conference, to be held virtually from 13-15 September 2021 (Press release, Kazia Therapeutics, SEP 10, 2021, https://www.prnewswire.com/news-releases/kazia-therapeutics-to-present-at-hc-wainwright-23rd-annual-global-investment-conference-301373181.html [SID1234587563]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The HC Wainwright Annual Global Investment Conference is one of the key events in the investor calendar and Kazia’s participation comes at an important time for the company. Kazia’s lead program, paxalisib, is currently in a pivotal study for glioblastoma, the most common and most aggressive form of brain cancer. If successful, paxalisib has the potential to become the first new drug treatment for newly diagnosed patients in almost twenty years, addressing a market worth US$ 1.5 billion per annum. More than 12,500 patients are diagnosed with glioblastoma each year, and the current standard of care treatment, temozolomide, is ineffective for approximately two-thirds of cases.
Dr Garner will provide an overview of Kazia’s key developments during FY2021, including:
Commencement of the GBM AGILE pivotal study for paxalisib in January 2021;
Out-licensing deal with Simcere Pharmaceutical for Greater China rights to paxalisib in March 2021, realizing an US$11 million upfront consideration;
Transformative in-licensing of EVT801 from Evotec, providing the company with a highly attractive second oncology asset.
Dr Garner will also share insights on Kazia’s objectives for FY2022 and outline the rich suite of catalysts that the company expects to announce during the remainder of CY2021.
This year’s HC Wainwright Annual Global Investment Conference will be conducted virtually from Monday 13th to Wednesday 15th and will feature more than 850 presenting companies, as well as a keynote presentation from Dr Scott Gottleib, former commissioner of the FDA.
Dr Garner commented, "Kazia’s presentation will be available to attendees on-demand, while the company will also meet individually with key investors and analysts over the duration of the conference to further advocate on behalf of the company’s compelling story."